Japan Looks At Drug Development To Deal With Rising Medical Expenses
This article was originally published in PharmAsia News
Executive Summary
Japan faces the same realities involving rising national medical expenses as other developed nations; it is expected to pass the $505 billion mark this year and increase at the rate of $1.6 billion a year.
You may also be interested in...
Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides Targets $200-400m From Generic Injectables In Mid-Term
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott Readying Vildagliptin ER In India Amid Price Competition
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Need a specific report? 1000+ reports available
Buy Reports